drugset
drugset / Trial / NCT05581823

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

NCT05581823 ↗

Phase 1 Completed 16 enrolled Cerevel Therapeutics, LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.

Timeline

Start
2022-10-19
Primary completion
2023-01-27
Completion
2023-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject Tavapadon Small molecule — Oral

Indications

Parkinson disease